BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

 BeiGene Reports Results of Tislelizumab + CT in P-III RATIONALE 309 Study as 1L Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Shots:

  • The P-III RATIONALE 309 study involves assessing tislelizumab + gemcitabine + cisplatin vs PBO combined with gemcitabine + cisplatin as a 1L treatment in 263 patients in a ratio (1:1) with recurrent or metastatic NPC
  • The study met its 1EPs of PFS at the interim analysis while the safety profile is consistent with its known risks, with no new safety signals identified with the addition of CT
  • Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 mAb, designed to minimize binding to FcγR on macrophages

Click here to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post